Weight-loss drugs are big business. Novo Nordisk’s blockbuster offering Wegovy is expected to be approved for sale in China this year. That would be another boost for the Danish company. But battered local drugmaker shares have even bigger upside potential.
减肥药是门大生意。诺和诺德(Novo Nordisk)的重磅产品Wegovy预计将于今年在manbetx3.0 获批上市。这对这家丹麦公司来说是又一大提振。但是，遭到重创的manbetx3.0 本土制药企业的股价还有更大的上涨潜力。
您已阅读10%（355字），剩余90%（3191字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。